The incidence of the metabolic syndrome has taken epidemic proportions in the past
decades, contributing to an increased risk of cardiovascular disease and diabetes. The …

HDL metabolism represents a major target for the development of therapies intended to
reduce the risk of atherosclerotic cardiovascular disease. HDL metabolism is complex and …

Bile acids are the end products of cholesterol metabolism. They are synthesized in the liver
and secreted via bile into the intestine, where they aid in the absorption of fat-soluble …

Dyslipidemia is an important risk factor for cardiovascular disease (CVD) and
atherosclerosis. When dyslipidemia coincides with other metabolic disorders such as …

Vertebrate members of the nuclear receptor NR5A subfamily, which includes steroidogenic
factor 1 (SF-1) and liver receptor homolog 1 (LRH-1), regulate crucial aspects of …

Small heterodimer partner (SHP, NR0B2) is a unique member of the nuclear receptor (NR)
superfamily that contains the dimerization and ligand-binding domain found in other family …

3D (three-dimensional) cultures are considered to be an effective method for toxicological
studies; however, little evidence has been reported whether 3D cultures have an impact on …

The last 20 years have witnessed dramatic reductions in cardiovascular risk using 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors (“statins”) to lower levels of low-density …

Bile acids (BAs) are water-soluble end products from cholesterol metabolism and are
essential for efficient absorption of dietary lipids. By using targeted somatic mutagenesis of …

Liver receptor homolog 1 (LRH-1), an established regulator of cholesterol and bile acid
homeostasis, has recently emerged as a potential drug target for liver disease. Although …